Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

Dow Jones

May 07, 2025

0810 GMT - Novo Nordisk's guidance cut is slightly greater than expected, with sales expectations lowered 3 percentage points and leaving consensus above the top end of the range, Jefferies analysts write. The EBIT target was also cut 3 percentage points. The lowered outlooks for sales and profit are likely 1-2 percentage points greater than expected, though potential consensus downgrades are likely greater due to currency. Sales of Wegovy missed by 7%, whilst Ozempic beat by 3%. Lower research and development and sales and distribution costs drove a 4% EBIT and 5% EPS beat. Focus now shifts to Wegovy trends and additional data readouts at the American Diabetes Association conference in June, Jefferies says. Shares rise 4.8%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

May 07, 2025 04:10 ET (08:10 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533673193"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533673193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533673193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533673193","market":"sh","top_or_hot":-1,"title":"Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0810 GMT - Novo Nordisk's guidance cut is slightly greater than expected, with sales expectations lowered 3 percentage points and leaving consensus above the top end of the range, Jefferies analysts write. The EBIT target was also cut 3 percentage points. The lowered outlooks for sales and profit are likely 1-2 percentage points greater than expected, though potential consensus downgrades are likely greater due to currency. Sales of Wegovy missed by 7%, whilst Ozempic beat by 3%. Lower research and development and sales and distribution costs drove a 4% EBIT and 5% EPS beat. Focus now shifts to Wegovy trends and additional data readouts at the American Diabetes Association conference in June, Jefferies says. Shares rise 4.8%. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 04:10 ET (08:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-07 16:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0810 GMT - Novo Nordisk's guidance cut is slightly greater than expected, with sales expectations lowered 3 percentage points and leaving consensus above the top end of the range, Jefferies analysts write. The EBIT target was also cut 3 percentage points. The lowered outlooks for sales and profit are likely 1-2 percentage points greater than expected, though potential consensus downgrades are likely greater due to currency. Sales of Wegovy missed by 7%, whilst Ozempic beat by 3%. Lower research and development and sales and distribution costs drove a 4% EBIT and 5% EPS beat. Focus now shifts to Wegovy trends and additional data readouts at the American Diabetes Association conference in June, Jefferies says. Shares rise 4.8%. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2025 04:10 ET (08:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533673193","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533673193","pubTimestamp":1746605400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0810 GMT - Novo Nordisk's guidance cut is slightly greater than expected, with sales expectations lowered 3 percentage points and leaving consensus above the top end of the range, Jefferies analysts write. The EBIT target was also cut 3 percentage points. The lowered outlooks for sales and profit are likely 1-2 percentage points greater than expected, though potential consensus downgrades are likely greater due to currency. Sales of Wegovy missed by 7%, whilst Ozempic beat by 3%. Lower research and development and sales and distribution costs drove a 4% EBIT and 5% EPS beat. Focus now shifts to Wegovy trends and additional data readouts at the American Diabetes Association conference in June, Jefferies says. Shares rise 4.8%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","BK4599":"减肥药","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"诺和诺德下调指引略高于预期——市场讨论","themeId":"4a89bf3a2d6a4841d9dc67eb820fcc8a","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0810 GMT - Novo Nordisk's guidance cut is slightly greater than expected, with sales expectations lowered 3 percentage points and leaving consensus above the top end of the range, Jefferies analysts write. The EBIT target was also cut 3 percentage points. The lowered outlooks for sales and profit are likely 1-2 percentage points greater than expected, though potential consensus downgrades are likely greater due to currency. Sales of Wegovy missed by 7%, whilst Ozempic beat by 3%. Lower research and development and sales and distribution costs drove a 4% EBIT and 5% EPS beat. Focus now shifts to Wegovy trends and additional data readouts at the American Diabetes Association conference in June, Jefferies says. Shares rise 4.8%. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2025 04:10 ET (08:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}